UK chemical sector growth, including pharmaceuticals, is forecast
at 3.6 per cent for 2004, outperforming the 2.3 per cent growth
estimated for Europe as a whole, according to a study presented at
the Chemical Industry Association's...
Filtration specialist Millipore has reported strong growth in sales
in the fourth quarter of 2003, suggesting that the fortunes of the
biopharmaceutical industry - Millipore's primary customer - may be
on the up.
Healthcare giant Cardinal Health reported revenues up 11 per cent
to $14.1 billion (€11.2bn) in the fourth-quarter of 2003, as a
strong performance in its pharmaceutical manufacturing services,
pharmacy automation and medical product...
A survey has found that difficulties in swallowing pills is
widespread among adults, but is rarely discussed with doctors and
can prevent some people from taking their medicine. The findings
suggest that pharmaceutical companies should...
The amount of pharmaceutical R&D funding headed out-of-house to
research suppliers engaged in drug development work will grow
almost 15 per cent annually for the next five years, nearly double
the anticipated increase in overall...
Filtration and purification specialist Pall has reported a 12.5 per
cent hike in first-quarter sales to $374 million (€310m), with life
sciences putting in a strong showing, up 15.5 per cent to $152
million.
Agilent returns to profit for the first time in two years in the
fourth quarter ended October 31, as cost-cutting compensated for a
modest decline in revenues.
Eastern European company Pliva has reported a 20 per cent hike in
sales for the third quarter of 2003 that concealed a major
contraction in the firm's fine chemicals business.
Tecan's third-quarter results reveal a mixed picture across the
group, with proteomics/genomics put in a good good performance but
drug discovery sales fell by a quarter.
PerkinElmer sees the benefit of a cost-cutting effort in its
third-quarter results as net income rises 45 per cent, but
biopharma puts in a lacklustre performance.
PerkinElmer sees the benefit of a cost-cutting effort in its
third-quarter results as net income rises 45 per cent, but
biopharma puts in a lacklustre performance.
Pall has reported a 10 per cent rise in sales to $471 million
(€430m) in the fourth quarter, boosted by currencies and the
recently-acquired FSG operations.
Degussa follows its peers in the speciality chemicals industry by
posting weak interim results held back by currency factors, raw
material costs and lower demand.
US pharmaceutical major Pfizer reinforced its position as the
world's largest drug company in 2002 after putting in sales of
$29.45 billion (€25.12 bn) in 2002, a hike of 11 per cent over the
prior year, according to a new analysis...
Millipore, which specialises in providing technologies, tools and
services for the discovery, development and production of new
therapeutic drugs, has reported first-quarter 2003 sales of $187
million (€173 million), up 13 per cent...
UK contract pharmaceutical manufacturer and distributor Intercare
Group has reported 2002 turnover of £275.1 million (€406m), an
increase of 27 per cent year-on-year, and pretax profits of £24.6
million, up 15 per cent. The results...
European scientists continue to be strong in areas such as medical
research and chemistry and Europe may produce the highest number of
science graduates but it is lagging behind in biotechnology, still
employs fewer researchers, accounts...
